Skip to main content
Journal cover image

Public perspectives about pharmacogenetic testing and managing ancillary findings.

Publication ,  Journal Article
Haga, SB; Tindall, G; O'Daniel, JM
Published in: Genet Test Mol Biomarkers
March 2012

AIMS: Pharmacogenetic (PGx) tests are intended to improve therapeutic outcomes through predicting a patient's likelihood to respond to or experience an adverse effect from a specific treatment. In addition, PGx testing may also generate ancillary, or incidental, disease information unrelated to the purpose for which the test was ordered. To assess public attitudes toward PGx testing, ancillary disease risk information and related clinical issues, we conducted a series of focus groups. RESULTS: Forty-five individuals recruited from Durham, NC, participated in four focus groups. Overall, participants were enthusiastic about PGx testing, though expressed concerns about privacy, confidentiality, and psychological harms associated with ancillary information. Focus group participants believed that physicians had a responsibility to disclose ancillary risk information, but were concerned about managing and coping with unexpected disease risk information. CONCLUSION: We find that participants welcomed the integration of PGx testing into therapeutic decision-making. Public concerns about PGx testing and ancillary information specifically centered on personal implications of learning such additional information, suggesting that patient-provider discussion of the benefits and risks of testing will be necessary until public familiarity with these tests increases.

Duke Scholars

Published In

Genet Test Mol Biomarkers

DOI

EISSN

1945-0257

Publication Date

March 2012

Volume

16

Issue

3

Start / End Page

193 / 197

Location

United States

Related Subject Headings

  • Young Adult
  • Public Opinion
  • Pharmacogenetics
  • Middle Aged
  • Male
  • Incidental Findings
  • Humans
  • Genetics & Heredity
  • Genetic Testing
  • Genetic Counseling
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Haga, S. B., Tindall, G., & O’Daniel, J. M. (2012). Public perspectives about pharmacogenetic testing and managing ancillary findings. Genet Test Mol Biomarkers, 16(3), 193–197. https://doi.org/10.1089/gtmb.2011.0118
Haga, Susanne B., Genevieve Tindall, and Julianne M. O’Daniel. “Public perspectives about pharmacogenetic testing and managing ancillary findings.Genet Test Mol Biomarkers 16, no. 3 (March 2012): 193–97. https://doi.org/10.1089/gtmb.2011.0118.
Haga SB, Tindall G, O’Daniel JM. Public perspectives about pharmacogenetic testing and managing ancillary findings. Genet Test Mol Biomarkers. 2012 Mar;16(3):193–7.
Haga, Susanne B., et al. “Public perspectives about pharmacogenetic testing and managing ancillary findings.Genet Test Mol Biomarkers, vol. 16, no. 3, Mar. 2012, pp. 193–97. Pubmed, doi:10.1089/gtmb.2011.0118.
Haga SB, Tindall G, O’Daniel JM. Public perspectives about pharmacogenetic testing and managing ancillary findings. Genet Test Mol Biomarkers. 2012 Mar;16(3):193–197.
Journal cover image

Published In

Genet Test Mol Biomarkers

DOI

EISSN

1945-0257

Publication Date

March 2012

Volume

16

Issue

3

Start / End Page

193 / 197

Location

United States

Related Subject Headings

  • Young Adult
  • Public Opinion
  • Pharmacogenetics
  • Middle Aged
  • Male
  • Incidental Findings
  • Humans
  • Genetics & Heredity
  • Genetic Testing
  • Genetic Counseling